Risk of surgical site infection in 401 consecutive patients with glioblastoma with and without carmustine wafer implantation

Kaisorn L. Chaichana, Lyonell Kone, Chetan Bettegowda, Jon D. Weingart, Alessandro Olivi, Michael Lim, Alfredo Quinones-Hinojosa, Gary L. Gallia, Henry Brem

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objectives: Patients with glioblastoma (GBM) have an inherently shortened survival because of their disease. It has been recently shown that carmustine wafers in addition to other therapies (surgery, temozolomide, and radiation) can further extend survival. There is concern, however, that these therapies may increase infection risk. The goals of this study were to calculate the incidence of postoperative infection, evaluate if carmustine wafers changes the risk of infection and identify factors independently associated with an infection following GBM surgery. Methods: All patients who underwent non-biopsy, surgical resection of an intracranial GBM from 2007 to 2011 at a single institution were retrospectively reviewed. Stepwise multivariate proportional hazards regression analysis was used to identify factors associated with infection, including the use of carmustine wafers. Variables with P < 0.05 were considered statistically significant. Results: Four hundred and one patients underwent resection of an intracranial GBM during the reviewed period, and 21 (5%) patients developed an infection at a median time of 40 [28–286] days following surgery. The incidence of infection was not higher in patients who had carmustine wafers, and this remained true in multivariate analyses to account for differences in treatment cohorts. The factors that remained significantly associated with an increased risk of infection were prior surgery [RR (95% CI); 2.026 (1.473– 4.428), P = 0.01], diabetes mellitus [RR (95% CI); 6.090 (1.380–9.354)], P = 0.02], and increasing duration of hospital stay [RR (95% CI); 1.048 (1.006–1.078); P = 0.02], where the greatest risk occurred with hospital stays >5 days [RR (95% CI); 3.904 (1.003–11.620), P = 0.05]. Discussion: These findings may help guide treatment regimens aimed at minimizing infection for patients with GBM.

Original languageEnglish (US)
Pages (from-to)717-726
Number of pages10
JournalNeurological Research
Volume37
Issue number8
DOIs
StatePublished - Aug 1 2015
Externally publishedYes

Fingerprint

Surgical Wound Infection
Carmustine
Glioblastoma
Infection
temozolomide
Survival
Therapeutics
Regression Analysis
Radiation
Incidence

Keywords

  • Carmustine (Gliadel) wafers
  • Glioblastoma (GBM)
  • Infection
  • Risk
  • Surgery

ASJC Scopus subject areas

  • Medicine(all)
  • Neurology
  • Clinical Neurology

Cite this

Risk of surgical site infection in 401 consecutive patients with glioblastoma with and without carmustine wafer implantation. / Chaichana, Kaisorn L.; Kone, Lyonell; Bettegowda, Chetan; Weingart, Jon D.; Olivi, Alessandro; Lim, Michael; Quinones-Hinojosa, Alfredo; Gallia, Gary L.; Brem, Henry.

In: Neurological Research, Vol. 37, No. 8, 01.08.2015, p. 717-726.

Research output: Contribution to journalArticle

Chaichana, Kaisorn L. ; Kone, Lyonell ; Bettegowda, Chetan ; Weingart, Jon D. ; Olivi, Alessandro ; Lim, Michael ; Quinones-Hinojosa, Alfredo ; Gallia, Gary L. ; Brem, Henry. / Risk of surgical site infection in 401 consecutive patients with glioblastoma with and without carmustine wafer implantation. In: Neurological Research. 2015 ; Vol. 37, No. 8. pp. 717-726.
@article{4eda4cd3aad8477ebdc56c94addd7699,
title = "Risk of surgical site infection in 401 consecutive patients with glioblastoma with and without carmustine wafer implantation",
abstract = "Objectives: Patients with glioblastoma (GBM) have an inherently shortened survival because of their disease. It has been recently shown that carmustine wafers in addition to other therapies (surgery, temozolomide, and radiation) can further extend survival. There is concern, however, that these therapies may increase infection risk. The goals of this study were to calculate the incidence of postoperative infection, evaluate if carmustine wafers changes the risk of infection and identify factors independently associated with an infection following GBM surgery. Methods: All patients who underwent non-biopsy, surgical resection of an intracranial GBM from 2007 to 2011 at a single institution were retrospectively reviewed. Stepwise multivariate proportional hazards regression analysis was used to identify factors associated with infection, including the use of carmustine wafers. Variables with P < 0.05 were considered statistically significant. Results: Four hundred and one patients underwent resection of an intracranial GBM during the reviewed period, and 21 (5{\%}) patients developed an infection at a median time of 40 [28–286] days following surgery. The incidence of infection was not higher in patients who had carmustine wafers, and this remained true in multivariate analyses to account for differences in treatment cohorts. The factors that remained significantly associated with an increased risk of infection were prior surgery [RR (95{\%} CI); 2.026 (1.473– 4.428), P = 0.01], diabetes mellitus [RR (95{\%} CI); 6.090 (1.380–9.354)], P = 0.02], and increasing duration of hospital stay [RR (95{\%} CI); 1.048 (1.006–1.078); P = 0.02], where the greatest risk occurred with hospital stays >5 days [RR (95{\%} CI); 3.904 (1.003–11.620), P = 0.05]. Discussion: These findings may help guide treatment regimens aimed at minimizing infection for patients with GBM.",
keywords = "Carmustine (Gliadel) wafers, Glioblastoma (GBM), Infection, Risk, Surgery",
author = "Chaichana, {Kaisorn L.} and Lyonell Kone and Chetan Bettegowda and Weingart, {Jon D.} and Alessandro Olivi and Michael Lim and Alfredo Quinones-Hinojosa and Gallia, {Gary L.} and Henry Brem",
year = "2015",
month = "8",
day = "1",
doi = "10.1179/1743132815Y.0000000042",
language = "English (US)",
volume = "37",
pages = "717--726",
journal = "Neurological Research",
issn = "0161-6412",
publisher = "Maney Publishing",
number = "8",

}

TY - JOUR

T1 - Risk of surgical site infection in 401 consecutive patients with glioblastoma with and without carmustine wafer implantation

AU - Chaichana, Kaisorn L.

AU - Kone, Lyonell

AU - Bettegowda, Chetan

AU - Weingart, Jon D.

AU - Olivi, Alessandro

AU - Lim, Michael

AU - Quinones-Hinojosa, Alfredo

AU - Gallia, Gary L.

AU - Brem, Henry

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Objectives: Patients with glioblastoma (GBM) have an inherently shortened survival because of their disease. It has been recently shown that carmustine wafers in addition to other therapies (surgery, temozolomide, and radiation) can further extend survival. There is concern, however, that these therapies may increase infection risk. The goals of this study were to calculate the incidence of postoperative infection, evaluate if carmustine wafers changes the risk of infection and identify factors independently associated with an infection following GBM surgery. Methods: All patients who underwent non-biopsy, surgical resection of an intracranial GBM from 2007 to 2011 at a single institution were retrospectively reviewed. Stepwise multivariate proportional hazards regression analysis was used to identify factors associated with infection, including the use of carmustine wafers. Variables with P < 0.05 were considered statistically significant. Results: Four hundred and one patients underwent resection of an intracranial GBM during the reviewed period, and 21 (5%) patients developed an infection at a median time of 40 [28–286] days following surgery. The incidence of infection was not higher in patients who had carmustine wafers, and this remained true in multivariate analyses to account for differences in treatment cohorts. The factors that remained significantly associated with an increased risk of infection were prior surgery [RR (95% CI); 2.026 (1.473– 4.428), P = 0.01], diabetes mellitus [RR (95% CI); 6.090 (1.380–9.354)], P = 0.02], and increasing duration of hospital stay [RR (95% CI); 1.048 (1.006–1.078); P = 0.02], where the greatest risk occurred with hospital stays >5 days [RR (95% CI); 3.904 (1.003–11.620), P = 0.05]. Discussion: These findings may help guide treatment regimens aimed at minimizing infection for patients with GBM.

AB - Objectives: Patients with glioblastoma (GBM) have an inherently shortened survival because of their disease. It has been recently shown that carmustine wafers in addition to other therapies (surgery, temozolomide, and radiation) can further extend survival. There is concern, however, that these therapies may increase infection risk. The goals of this study were to calculate the incidence of postoperative infection, evaluate if carmustine wafers changes the risk of infection and identify factors independently associated with an infection following GBM surgery. Methods: All patients who underwent non-biopsy, surgical resection of an intracranial GBM from 2007 to 2011 at a single institution were retrospectively reviewed. Stepwise multivariate proportional hazards regression analysis was used to identify factors associated with infection, including the use of carmustine wafers. Variables with P < 0.05 were considered statistically significant. Results: Four hundred and one patients underwent resection of an intracranial GBM during the reviewed period, and 21 (5%) patients developed an infection at a median time of 40 [28–286] days following surgery. The incidence of infection was not higher in patients who had carmustine wafers, and this remained true in multivariate analyses to account for differences in treatment cohorts. The factors that remained significantly associated with an increased risk of infection were prior surgery [RR (95% CI); 2.026 (1.473– 4.428), P = 0.01], diabetes mellitus [RR (95% CI); 6.090 (1.380–9.354)], P = 0.02], and increasing duration of hospital stay [RR (95% CI); 1.048 (1.006–1.078); P = 0.02], where the greatest risk occurred with hospital stays >5 days [RR (95% CI); 3.904 (1.003–11.620), P = 0.05]. Discussion: These findings may help guide treatment regimens aimed at minimizing infection for patients with GBM.

KW - Carmustine (Gliadel) wafers

KW - Glioblastoma (GBM)

KW - Infection

KW - Risk

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=84933523402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933523402&partnerID=8YFLogxK

U2 - 10.1179/1743132815Y.0000000042

DO - 10.1179/1743132815Y.0000000042

M3 - Article

C2 - 25916669

AN - SCOPUS:84933523402

VL - 37

SP - 717

EP - 726

JO - Neurological Research

JF - Neurological Research

SN - 0161-6412

IS - 8

ER -